3,204 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Acquired by Grandfield & Dodd LLC

Grandfield & Dodd LLC acquired a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 3,204 shares of the biopharmaceutical company’s stock, valued at approximately $964,000.

Several other hedge funds also recently bought and sold shares of the business. Brighton Jones LLC purchased a new stake in Alnylam Pharmaceuticals in the fourth quarter worth $243,000. Geneos Wealth Management Inc. boosted its stake in shares of Alnylam Pharmaceuticals by 372.3% during the first quarter. Geneos Wealth Management Inc. now owns 222 shares of the biopharmaceutical company’s stock valued at $60,000 after purchasing an additional 175 shares during the period. Flow Traders U.S. LLC bought a new position in shares of Alnylam Pharmaceuticals in the second quarter worth about $241,000. Daiwa Securities Group Inc. grew its holdings in shares of Alnylam Pharmaceuticals by 0.3% in the second quarter. Daiwa Securities Group Inc. now owns 12,941 shares of the biopharmaceutical company’s stock worth $4,220,000 after purchasing an additional 35 shares during the last quarter. Finally, NewEdge Advisors LLC increased its stake in Alnylam Pharmaceuticals by 70,300.0% in the 2nd quarter. NewEdge Advisors LLC now owns 704 shares of the biopharmaceutical company’s stock worth $229,000 after buying an additional 703 shares during the period. Institutional investors own 92.97% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on ALNY. Citigroup decreased their price objective on shares of Alnylam Pharmaceuticals from $380.00 to $340.00 and set a “buy” rating for the company in a report on Monday, August 3rd. Needham & Company LLC dropped their target price on shares of Alnylam Pharmaceuticals from $510.00 to $357.00 and set a “buy” rating on the stock in a research note on Thursday, July 30th. Wells Fargo & Company reduced their target price on shares of Alnylam Pharmaceuticals from $316.00 to $256.00 and set an “equal weight” rating on the stock in a research report on Friday. Sanford C. Bernstein raised shares of Alnylam Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, July 29th. Finally, JPMorgan Chase & Co. lowered their price target on Alnylam Pharmaceuticals from $400.00 to $375.00 and set an “overweight” rating for the company in a report on Friday, July 31st. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Alnylam Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $393.86.

Insider Activity at Alnylam Pharmaceuticals

In other news, Director David E. I. Pyott sold 3,830 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $299.18, for a total value of $1,145,859.40. Following the completion of the sale, the director owned 1,582 shares of the company’s stock, valued at approximately $473,302.76. This represents a 70.77% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.86% of the company’s stock.

Alnylam Pharmaceuticals Stock Performance

ALNY stock opened at $224.60 on Tuesday. The company has a debt-to-equity ratio of 0.75, a current ratio of 3.05 and a quick ratio of 2.99. The business has a 50-day moving average price of $271.51 and a 200 day moving average price of $300.10. The company has a market capitalization of $30.05 billion, a P/E ratio of 41.75 and a beta of 0.30. Alnylam Pharmaceuticals, Inc. has a 1-year low of $197.81 and a 1-year high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.84 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.63 by $0.21. Alnylam Pharmaceuticals had a net margin of 15.26% and a return on equity of 84.93%. The company had revenue of $1.29 billion for the quarter, compared to analysts’ expectations of $1.32 billion. During the same period in the prior year, the business earned ($0.51) EPS. The firm’s quarterly revenue was up 66.9% on a year-over-year basis. As a group, equities research analysts forecast that Alnylam Pharmaceuticals, Inc. will post 6.59 EPS for the current fiscal year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.